Financial markets

EQS-News: Patrimonium Private Equity Fund invests in Octo Actuators

Thursday, July 29, 2021 - 10:01am

Zrich, July 29, 2021 - Patrimonium Private Equity invests in Octo Actuators, a fast growing leader in the sector of integrated drive systems for the bed and furniture industry.

Key Points: 
  • Zrich, July 29, 2021 - Patrimonium Private Equity invests in Octo Actuators, a fast growing leader in the sector of integrated drive systems for the bed and furniture industry.
  • Patrimonium Private Equity is taking a stake in the group's Swiss holding company and will support future growth through capital increases.
  • www.octo-actuators.de
    Patrimonium Private Equity Advisors AG ("Patrimonium Private Equity") advises the Patrimonium Private Equity Fund SCSp and is a part of Patrimonium Asset Management AG (Patrimonium).
  • Patrimonium is a Swiss private markets investment manager operating across the real estate, private debt, private equity and infrastructure asset classes.

Darwinex: UK-based FinTech Darwinex Secures €3 Million In Growth Funding

Thursday, July 29, 2021 - 9:01am

The Fintech, broker and asset management company Darwinex has raised 3 million to pursue its ambitious growth aspirations.

Key Points: 
  • The Fintech, broker and asset management company Darwinex has raised 3 million to pursue its ambitious growth aspirations.
  • Pinorena Capital, a fintech-focused investment company led by entrepreneur Illimar Mattus, has contributed with this first investment to supporting Darwinex expansion journey.
  • Darwinex is regulated by the FCA in the UK (Tradeslide Trading TechLimited - FRN 586466) and its latest financial figures show revenue for the financial year 2020 jumping by 72%, exceeding 4.69 million.
  • Darwinex unique front-to-back Fintech solution enables successful traders and small to medium-sized hedge funds to easily convert its trading strategies into investable assets.

DGAP-News: Darwinex: UK-based FinTech Darwinex Secures €3 Million In Growth Funding

Thursday, July 29, 2021 - 9:01am

The Fintech, broker and asset management company Darwinex has raised 3 million to pursue its ambitious growth aspirations.

Key Points: 
  • The Fintech, broker and asset management company Darwinex has raised 3 million to pursue its ambitious growth aspirations.
  • Leading investors in the round were Stefan Jaecklin and Pinorena Capital who were joined by Darwinex co-founders and a number of key employees in the company.
  • Pinorena Capital, a fintech-focused investment company led by entrepreneur Illimar Mattus, has contributed with this first investment to supporting Darwinex expansion journey.
  • Darwinex unique front-to-back Fintech solution enables successful traders and small to medium-sized hedge funds to easily convert its trading strategies into investable assets.

EQS-News: Darwinex: UK-based FinTech Darwinex Secures €3 Million In Growth Funding

Thursday, July 29, 2021 - 9:00am

The Fintech, broker and asset management company Darwinex has raised 3 million to pursue its ambitious growth aspirations.

Key Points: 
  • The Fintech, broker and asset management company Darwinex has raised 3 million to pursue its ambitious growth aspirations.
  • Pinorena Capital, a fintech-focused investment company led by entrepreneur Illimar Mattus, has contributed with this first investment to supporting Darwinex expansion journey.
  • Darwinex is regulated by the FCA in the UK (Tradeslide Trading TechLimited - FRN 586466) and its latest financial figures show revenue for the financial year 2020 jumping by 72%, exceeding 4.69 million.
  • Darwinex unique front-to-back Fintech solution enables successful traders and small to medium-sized hedge funds to easily convert its trading strategies into investable assets.

Patrimonium Private Equity Fund invests in Octo Actuators

Thursday, July 29, 2021 - 9:00am

Patrimonium Private Equity invests in Octo Actuators, a fast growing leader in the sector of integrated drive systems for the bed and furniture industry.

Key Points: 
  • Patrimonium Private Equity invests in Octo Actuators, a fast growing leader in the sector of integrated drive systems for the bed and furniture industry.
  • Patrimonium Private Equity is taking a stake in the group's Swiss holding company and will support future growth through capital increases.
  • www.octo-actuators.de
    Patrimonium Private Equity Advisors AG ("Patrimonium Private Equity") advises the Patrimonium Private Equity Fund SCSp and is a part of Patrimonium Asset Management AG (Patrimonium).
  • Patrimonium is a Swiss private markets investment manager operating across the real estate, private debt, private equity and infrastructure asset classes.

Shell announces commencement of share buybacks

Thursday, July 29, 2021 - 7:03am

Royal Dutch Shell plc (the company) today announces the commencement of share buybacks as part of its move to the next phase of its capital allocation framework, which includes shareholder distributions in a range of 20-30% of CFFO.

Key Points: 
  • Royal Dutch Shell plc (the company) today announces the commencement of share buybacks as part of its move to the next phase of its capital allocation framework, which includes shareholder distributions in a range of 20-30% of CFFO.
  • The purpose of the share buybacks is to reduce the issued share capital of the company.
  • In this announcement Shell, Shell Group and Group are sometimes used for convenience where references are made to Royal Dutch Shell plc and its subsidiaries in general.
  • Subsidiaries, Shell subsidiaries and Shell companies as used in this announcement refer to entities over which Royal Dutch Shell plc either directly or indirectly has control.

Traeger Announces Pricing of Initial Public Offering

Thursday, July 29, 2021 - 4:57am

Traeger, Inc. (Traeger) announced today the pricing of its initial public offering of 23,529,411 shares of its common stock at a price to the public of $18.00 per share.

Key Points: 
  • Traeger, Inc. (Traeger) announced today the pricing of its initial public offering of 23,529,411 shares of its common stock at a price to the public of $18.00 per share.
  • The initial public offering is expected to close on August 2, 2021, subject to customary closing conditions.
  • Morgan Stanley, Jefferies, Baird, and William Blair are acting as joint lead book-running managers for the initial public offering.
  • A registration statement relating to the securities being sold in the initial public offering was declared effective by the U.S. Securities and Exchange Commission on July 28, 2021.

Algorithmic Trading Market 2021-2025: Industry Analysis, Market Trends, Growth, Opportunities and Forecasts | Technavio

Thursday, July 29, 2021 - 4:30am

The report on the algorithmic trading market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

Key Points: 
  • The report on the algorithmic trading market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment.
  • The algorithmic trading market analysis includes components and geography landscape segments.
  • This study identifies the rise in the integration of financial markets as one of the prime reasons driving the algorithmic trading market growth during the next few years.

Colfax Announces Pricing of Secondary Offering of 6,544,522 Shares of Common Stock

Thursday, July 29, 2021 - 3:14am

WILMINGTON, DE, July 28, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today the pricing of an underwritten secondary offering by certain of its stockholders (the “Selling Stockholders”) of 6,544,522 shares of the Company’s common stock at a public offering price of $43.90 per share. The shares are expected to be delivered on or about August 2, 2021, subject to customary closing conditions.

Key Points: 
  • WILMINGTON, DE, July 28, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (Colfax or the Company) (NYSE: CFX), a leading diversified technology company, announced today the pricing of an underwritten secondary offering by certain of its stockholders (the Selling Stockholders) of 6,544,522 shares of the Companys common stock at a public offering price of $43.90 per share.
  • The shares are expected to be delivered on or about August 2, 2021, subject to customary closing conditions.
  • The Company is not selling any shares of common stock in the offering and will not receive any proceeds from the offering.
  • Morgan Stanley is acting as sole book-running manager for the offering.

Icosavax Announces Pricing of Upsized Initial Public Offering

Thursday, July 29, 2021 - 3:13am

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the pricing of its upsized initial public offering of 12,133,333 shares of common stock at an initial public offering price of $15.00 per share.

Key Points: 
  • Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the pricing of its upsized initial public offering of 12,133,333 shares of common stock at an initial public offering price of $15.00 per share.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Icosavax, are expected to be approximately $182.0 million.
  • In addition, Icosavax has granted the underwriters a 30-day option to purchase up to an additional 1,819,999 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases.